NASDAQ:CRVSCorvus Pharmaceuticals Stock Price, Forecast & News

$3.31

+0.06 (+1.85 %)

(As of 06/5/2020 03:12 PM ET)

Add

Compare

Today's Range

$3.25

Now: $3.31▼

$3.59

50-Day Range

$2.15

MA: $3.10▼

$4.05

52-Week Range

$1.01

Now: $3.31▼

$8.10

Volume59,604 shs

Average Volume164,100 shs

Market Capitalization$92.51 million

P/E RatioN/A

Dividend YieldN/A

Beta2.08

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Corvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.33, Corvus Pharmaceuticals has a potential upside of 151.8% from its current price of $3.31.
Amount of Analyst Coverage
Corvus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Corvus Pharmaceuticals has received 260 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Corvus Pharmaceuticals has received 250 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Corvus Pharmaceuticals has received 50.98% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Corvus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corvus Pharmaceuticals does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
45.12% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
73.90% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corvus Pharmaceuticals is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corvus Pharmaceuticals is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corvus Pharmaceuticals has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CRVS

Previous Symbol

CUSIPN/A

CIK1626971

Webwww.corvuspharma.com

Phone650-900-4520

Debt

Debt-to-Equity Ratio0.03

Current Ratio5.96

Quick Ratio5.96

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.42 per share

Price / Book1.37

Profitability

EPS (Most Recent Fiscal Year)($1.59)

Net Income$-46,670,000.00

Net MarginsN/A

Return on Equity-63.69%

Return on Assets-54.35%

Miscellaneous

Employees49

Outstanding Shares27,950,000

Market Cap$92.51 million

Next Earnings Date8/6/2020 (Estimated)

OptionableNot Optionable

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

How has Corvus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRVS shares have increased by 22.1% and is now trading at $3.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Corvus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corvus Pharmaceuticals.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Corvus Pharmaceuticals.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) posted its quarterly earnings results on Thursday, April, 30th. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.04. View Corvus Pharmaceuticals' earnings history.

What price target have analysts set for CRVS?

3 Wall Street analysts have issued 1-year target prices for Corvus Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Corvus Pharmaceuticals' share price to reach $8.33 in the next year. This suggests a possible upside of 151.8% from the stock's current price. View analysts' price targets for Corvus Pharmaceuticals.

Has Corvus Pharmaceuticals been receiving favorable news coverage?

Media coverage about CRVS stock has been trending very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View the latest news aboutCorvus Pharmaceuticals.

Who are some of Corvus Pharmaceuticals' key competitors?

Some companies that are related to Corvus Pharmaceuticals include Urovant Sciences (UROV), Spectrum Pharmaceuticals (SPPI), Kamada (KMDA), Seres Therapeutics (MCRB), Wave Life Sciences (WVE), Selecta Biosciences (SELB), TherapeuticsMD (TXMD), Osmotica Pharmaceuticals (OSMT), Geron (GERN), Rigel Pharmaceuticals (RIGL), Bicycle Therapeutics (BCYC), Ovid Therapeutics (OVID), Verrica Pharmaceuticals (VRCA), OrganiGram (OGI) and MannKind (MNKD). View all competitors.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), ImmunoGen (IMGN) and Immunomedics (IMMU).

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:

Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
Mr. Leiv Lea, Chief Financial Officer (Age 65)
Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (0.36%), Connor Clark & Lunn Investment Management Ltd. (0.31%), Hikari Power Ltd (0.22%), Morgan Stanley (0.12%), Russell Investments Group Ltd. (0.11%) and Two Sigma Advisers LP (0.10%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View institutional ownership trends for Corvus Pharmaceuticals.

Which major investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Two Sigma Investments LP, and Morgan Stanley. View insider buying and selling activity for Corvus Pharmaceuticals.

Which major investors are buying Corvus Pharmaceuticals stock?

CRVS stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Two Sigma Advisers LP, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller. View insider buying and selling activity for Corvus Pharmaceuticals.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $3.31.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $92.51 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Corvus Pharmaceuticals employs 49 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff